Follow Us:

social twitter box white 32 social facebook box blue 32social linkedin box blue 32YoutubeISN Blog

Wednesday, 19 September 2018 09:34

2018 KDIGO hepatitis C in CKD guideline now available! Featured

By  Publications
Rate this item
(0 votes)

kdigoAn executive summary of the 2018 KDIGO hepatitis C in CKD guideline: Welcoming advances in evaluation and management is now available in Kidney International. 

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant.

Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients.

In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline.

This Executive Summary highlights key aspects of the guideline recommendations. Read the executive summary.

ISN supports KDIGO guidelines dissemination through its journal and participates in planning meetings together with the KDIGO advisory board.

Visit Kidney International.

Read 683 times Last modified on Thursday, 20 September 2018 09:44

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact